Name (Synonyms) | Correlation | |
---|---|---|
drug346 | Hidroxicloroquina + Azitromicina o Lopinavir/ritonavir + Interferon β-1b + Hidroxicloroquina Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection.
Description: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).
Measure: Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE). Time: 30 days after enrollmentDescription: IL-6> 40 pg / mL, D-dimer> 1500, ferritin> 1000ng / mL.
Measure: Efficacy: Any of the following analytical data after 72h of randomization. Time: Day +21 after randomizationDescription: IL-6> 40 pg / mL, D-dimer> 1500, ferritin> 1000ng / mL until the cure test.
Measure: Efficacy: Proportion of patients who develop analytical alterations. Time: Day +21 after randomization.